米非司酮配伍卡前列甲酯89例与米非司酮配伍米索前列醇110例终止早期妊娠的比较

目的：比较米非司酮配伍卡前列甲酯与米非司酮配伍米索前列醇终止早期妊娠的疗效。方法：妊娠≤４９ｄ孕妇１９９例，年龄２６±５ａ，随机分Ａ组８９例，Ｂ组１１０例。２组均用米非司酮２５ｍｇ，ｂｉｄ，３ｄ，于ｄ４，Ａ组阴道后穹窿置卡前列甲酯栓１ｍｇ。Ｂ组米索前列醇ｐｏ，６００μｇ。结果：Ａ和Ｂ组完全流产率各为８３％和９３．６％，经Ｘ２检验，Ｐ＜０．０５；胎囊排出时间，Ａ组４±５ｈ，Ｂ组３±６ｈ，２组无显著差异。结论：米非司酮配伍米索前列醇的抗早孕效果优于配伍卡前列甲酯。     

Update on medication abortion

This article provides an overview of medication abortion in the United States 6 years after the approval of mifepristone (RU486; Mifeprex; Danco Laboratories, LLC, New York, NY) by the US Food and Drug Administration (FDA). The adoption of mifepristone is considered in the context of epidemiologic data on abortion, abortion access, and the safety of abortion. The risks of medication and aspiration abortion are discussed in the context of abortion-related mortality, recent experience with obstetric and gynecologic infection with Clostridium sordellii, and the limits of scientific knowledge on the incidence of this infection in women. Innovative protocols studied since FDA approval of mifepristone are presented, and implications for clinical practice are discussed.     

含服米索前列醇预防选择性剖宫产产后出血

目的：探讨舌下含服米索前列醇预防剖宫产产后出血的效果。方法：将妊娠晚期单胎选择性剖宫产者200例随机分为两组,研究组110例，在第二产程末胎头娩出后舌下含服米索400μg，对照组90例，在胎儿娩出后静脉注射催产素20IU，观察产后2h出血量和用米索前后血压及用药后出现的副作用，结果：产后2h内的出血量，研究组与对照组分别为174．43ml和219.73ml，二组比较有显著性差异（P＜0．01），用米索前后血压比较，二组无显著性差异（P＞0．05），结论：舌下含服前列醇促进子宫收缩作用强于催产素，能减少产后出血，也适用于某些与血管变化有关的高危孕产妇，预防产后出血。     

米非司酮配伍米索前列醇终止早孕用药方法的探讨

作者对１２０例妊娠４９ｄ以内的孕妇采用４种不同的服药方法进行药物流产，其中使用第３、４种用药方法的孕妇均于加用米索前列醇后８ｈ内排出孕囊，且２ｈ内排出率明显增加，与常规用药方法比较有显著性差异（Ｐ＜０．０１），同时对用药机理作了讨论。     

米非司酮配伍米索前列醇终止早孕118例临床观察

就米非司酮配伍采米前列醇序贯用药终止７周内早孕１１８例进行临床观察，发现完全流产率９２．３７％，不全流产率５．９３％，持续妊娠率１．６９％。临床证明该方法方便、安全有效、副作用极小，但个别孕妇产生不全流产，引起出血过多及出血时间延长。不全流产率有随孕妇年龄、孕龄、孕次增加而增加的趋势。     

米索前列醇的临床应用

米索前列醇（misoprostol,米索）是人工合成的前列腺素E_1的衍生物,有多方面临床用途。80年代早期米索最先开始用于治疗消化性溃疡,尤其是对非甾体类抗炎药引起的胃十二指肠溃疡有明显疗效,对急性应激性溃疡也有预防作用。米索可引起腹泻,但因此也可治疗严重便秘的患者。随后发现米索对肝、肾有保护作用,还具明显抗炎、抗过敏作用;与其它抗早孕药合用,米索可使完全流产率大大提高;对人工流产术前的病人用米索可软化并扩张宫颈,从而减轻扩宫时病人的痛苦,使手术顺利进行。对米索的毒副作用研究发现其毒性主要表现在消化系统和雄性生殖系统,但一般比较轻微,无明显其它不良反应。故米索可谓一种高效、低毒的药物,值得临床推广。但男性患者在长期大量应用该药时需注意其对生殖系统的影响,孕妇应禁用。     

Pregnancy: Oral misoprostol versus placebo for cervical dilatation before vacuum aspiration in first trimester pregnancy

Intravaginal misoprostol has been shown to be effective forcervical priming before a surgically induced abortion. The objectivewas to investigate the effectiveness of oral misoprostol incervical dilatation prior to vacuum aspiration between the 6thand 12th weeks of pregnancy. The results showed that in nulliparouspatients, the median cervical dilatation in the treatment group(7.8 mm) was significantly greater than that in the placebogroup (3.7 mm). In multiparous patients, the difference wasalso statistically significant (9.8 versus 6.0 mm). The easeof dilatation, assessed subjectively by the operating surgeons,was significantly improved in the treatment group. There wasalso a significant reduction in the duration of the operationand in the mean blood loss in the treatment group. The side-effectsencountered in the treatment group were mild and well acceptedby the women. Oral misoprostol is an effective and safe methodfor cervical dilatation prior to vacuum aspiration in firsttrimester pregnancy.     

A prospective randomized,double-blinded,placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of early pregnancy

BACKGROUND: Vaginal misoprostol has been shown to be an effective single agent for medical abortion. This randomized, double-blinded, placebo-controlled trial compared a regimen of mifepristone and misoprostol with misoprostol alone for termination of early pregnancy. METHODS: 250 women with gestations < or = 56 days were randomized by a random number table to receive either 200 mg mifepristone orally or placebo followed 48 h later by 800 microg vaginal misoprostol. Administration of misoprostol was repeated every 24 h up to three doses if abortion failed to occur. Abortion success was defined as complete abortion without the use of surgical aspiration. RESULTS: Successful medical abortions occurred in 114 out of 119 subjects (95.7%) after mifepristone followed by vaginal misoprostol. In all, 110 out of 125 subjects (88.0%) successfully aborted after placebo and vaginal misoprostol. The higher success rate of complete abortion with the mifepristone and misoprostol regimen was statistically significant compared with the placebo and misoprostol regimen (P < 0.05). CONCLUSIONS: A regimen of mifepristone and misoprostol was significantly more effective for termination of pregnancies < or = 56 days than misoprostol alone. The 88% efficacy obtained with vaginal misoprostol alone may be clinically acceptable when mifepristone is not available.     

An effective regimen for early medical abortion: a report of 2000 consecutive cases

A combination of the anti-progesterone mifepristone and gemeprostprovides an effective non-surgical method for the inductionof abortion at gestations up to 63 days, achieving completeabortion rates of over 95%. We report our experience with analternate regimen, comprising a reduced dose of mifepristonein combination with vaginal misoprostol. A consecutive seriesof 2000 women requesting early medical abortion at gestationsup to 63 days was studied retrospectively. Each woman receivedmifepristone 200 mg orally, followed 36–48 h later bymisoprostol 800 µg vaginally. Of the 2000 women, 39 (2.0%)aborted completely following administration of mifepristonealone and a further 1912 experienced complete abortion followingadministration of misoprostol (a complete abortion rate of 97.5%).Surgical intervention was required in 49 women (2.5%): for incompleteabortion in 27 (1.4%), for missed abortion in seven (0.4%),for continuing pregnancy in 11 (0.6%) and to exclude ectopicpregnancy in four (0.2%). The surgical intervention rate wassignificantly higher among women at gestations 49 days thanamong those at 49 days (3.3 versus 1.5%, P = 0.0193). The regimenappears as effective, in terms of high complete abortion rateand low continuing pregnancy rate, as any published alternative.This regimen has the benefit of being less costly as the doseof mifepristone is 67% lower and misoprostol is substantiallyless expensive than gemeprost. Additionally, misoprostol doesnot require special transport or storage requirements. As such,the combination of mifepristone and gemeprost.